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AIMS OF THE STUDY 
1. To study the outcome of patients of carcinoma cervix treated with 
neoadjuvant radiotherapy followed by Wertheim’s hysterectomy 
and bilateral pelvic dissection during a period of five years 
(2000-2004) in terms of pathological response rate, disease free 
survival and complications. 
 
2. To compare the outcome of study population with outcome of 
matched patients treated with definitive radiotherapy during the 
same time period. 
 [2] 
 
BACKGROUND 
Cervical cancer is the second most common cancer in women worldwide and 
one of the commonest female cancers in many developing countries. The mean 
age for cervical cancer is 51.4 years. Early diagnosis of cervical cancer can be 
challenging because of these factors: 
1. Frequently asymptomatic nature of early stage disease, 
2. Origin of some cancers from within the endocervical canal or beneath the 
epithelium of the ectocervix, making visualization on speculum 
examination difficult, 
3. Difficult access to health care and socioeconomic factors, 
4. Significant false negative rate for Pap smears, even in women having 
regular screening. 
Diagnosis of early stage invasive carcinoma cervix not only has the advantage 
of favourable outcome for the patients but also allows physicians to choose 
between treatment options available for a particular case depending on patients’ 
preference and desired side effect profile, whereas in advanced carcinoma 
cervix the choice of treatment is limited to chemoradiotherapy or chemotherapy. 
For early stage carcinoma cervix both radiotherapy and radical surgery are 
acceptable treatment options with comparable survival in most of the series. 
However a few studies have reported better survival for those patients who were 
treated with radical surgery upfront than those who were treated with definitive 
 [3] 
 
radiotherapy in early stage carcinoma cervix. The treatment of such cases is 
mostly based on institutional practice, preference of the treating physician and 
the patient. 
Surgery as definitive treatment is associated with better staging and 
identification of high risk features and directing adjuvant treatment to those 
patients who have indications for adjuvant therapy. Avoiding radical radiation 
in early stage disease also avoids the long term side effects of radiation like 
radiation cystitis and proctitis. The post-operative quality of sexual life after 
radiation is poor because of adhesive vaginitis, loss of lubrication and 
dyspareunia. Some authors also feel that surgery removes bulky nodes making 
adjuvant treatment more effective. On the contrary patients who need adjuvant 
treatment after radical surgery are subjected to morbidity of both modalities.  
In the natural history of cervical cancer following treatment the local 
recurrences are central mostly emphasising the need for radiation to vagina and 
vault.  Brachytherapy serves the purpose with the advantage of avoiding other 
organs in pelvis. 
The role of neoadjuvant chemoradiotherapy and chemotherapy for carcinoma 
cervix cases is supported by a few trials, however to best of our knowledge no 
study has ever compared neoadjuvant radiotherapy followed by radical surgery 
as definitive treatment of carcinoma cervix in early stage. 
 [4] 
 
By this study we aim at analysing the outcomes of those patients of early stage 
invasive carcinoma cervix treated with combination of both the modalities 
delivering less than radical radiotherapy before radical surgery, the theoretical 
advantage being able to avoid crossing tolerance of normal tissues and avoiding 
long term radiation side effects. 
[5] 
 
Material and methods 
This is a retrospective study of patients of invasive Cervical Cancer stage IA/IB 
and IIA, who underwent treatment in our institute between years 2000 to 2004. 
Eligible patients were those who received a course of less than radical 
radiotherapy by either intracavitary application or external beam radiotherapy. 
Our operation record registers were searched for the patients who underwent 
surgery for carcinoma cervix during the foresaid period, all the available records 
were scrutinized and details were entered in a standard format which was 
uniform for study and control population except surgery details which were 
applicable only to the study group. All patients underwent clinical examination 
before treatment by an experienced clinician, and haemogram, renal and hepatic 
function tests, coagulation profile as well as cardiac evaluation was done with 
standard metastatic work up. A biopsy confirmation of the disease was done and 
a clinical stage was assigned by the same physician to all patients. In the case of 
discrepancy between the findings of two clinicians, findings of the above 
mentioned clinician were considered for the purpose of this study. Whenever a 
single clinical stage could not be assigned due to ambiguous clinical findings 
and discrepancy occurred, the lower stage assigned was taken as the final stage. 
All available relevant information as symptoms and their duration, age at 
presentation, obstetric, reproductive history and family history were noted, 
comorbidities were noted to subsequently match with the control group, tumour 
[6] 
 
characteristics such as size, gross morphology and histology with grade were 
noted, preoperative treatment in form of brachytherapy or external beam 
radiotherapy was noted, total dose delivered and duration of treatment was also 
noted. Mean dose of radiation delivered by Intracavitary application was 23Gy 
whereas median dose of external beam radiation was 40Gy. Subsequently 
standard Wertheim’s hysterectomy with nodal dissection was performed,  
complications and time of their occurrence was noted till the last available 
follow up, final histopathology report was assessed for response including 
pathologic complete response and size of residue, margins on vaginal and 
parametrial aspect, lymph node yield, lymphovascular invasion and nodal 
positivity were noted. Adjuvant treatment given was noted, subsequent follow 
up, disease recurrence site and treatment given on recurrence were noted. 
A similarly matched control group who received treatment during the same time 
period (2000-2004) by definitive radiotherapy were studied using the same 
variables and compared, late and early complications were noted and compared. 
Inclusion Criteria: 
     1. Women with histologically proven invasive carcinoma of the uterine cervix, 
stages IA, IB, IIA. 
2. Age between 18-70 years. 
3. No evidence of visceral, skeletal or distant nodal metastases. 
[7] 
 
4. No history of past or coexisting second malignancy. 
5. Good performance status (Karnofsky performance score > 70 or ECOG PS 
<2). 
6. Normal hematologic & biochemical parameters. 
7. No prior treatment for the same cancer elsewhere. 
Exclusion criteria: 
1. All patients who did not have preoperative diagnosis of invasive cervical 
carcinoma. 
2. All patients who were too elderly to be considered for surgery. 
3. All patients who did not undergo standard Wertheim’s hysterectomy with 
bilateral pelvic dissection. 
4. Any preoperative uncontrolled comorbidity medical or otherwise which 
would lead to preference of one treatment over the other. 
5. Any patients not satisfying the inclusion criteria. 
All those patients who did not match with our study eligibility criteria were 
excluded from the study. All the patients were followed up by means of clinical 
examination monthly for the first month, once in two and three months for the 
second and third year and subsequently 6 monthly during the fourth year and 
yearly thereafter. Annually ultrasound abdomen, chest radiography were done, 
any suspicious clinical findings were evaluated further by appropriate tests.  
[8] 
 
Review of literature 
Cervical cancer is a common cancer and is one of the leading causes for which 
oncology opinion is sought in both developing and developed world. 
Unfortunately, in countries where penetrance of cervical cancer screening is 
poor, cervical cancer remains the second most common type of cancer (17.8 per 
100,000 women) and cause of cancer deaths (9.8 per 100,000) in women. The 
burden of disease in developed countries is also considerable, cancer of the 
cervix was third most common cancer diagnosis as well as cause of mortality  
among gynecologic cancers in the United States in 2011 [1]. The disease is 
usually seen at a mean age of around 45 years with peak distribution of cases 
between 35-39 years and 60-65 years. The five year survival for cases of 
cervical cancer vary with the stage at diagnosis, which is better for early stage 
disease and 5 year survival rate ranges from 93%-80% for stage I, 63%-58% for 
stage II, 35%-32% for stage III and 16%–14.6% for stage IV according to a 
study of 15070 cases from National cancer database in USA. Most common 
histology encountered is squamous cell carcinoma and adenocarcinoma, other 
rare types accounting only for a minority of cases and are generally associated 
with poor prognosis.  
Risk Factors 
Human papilloma virus is associated with around 99% of carcinoma cervix 
cases. Molecular and epidemiological studies have shown a strong correlation 
[9] 
 
between human papilloma virus infection, intraepithelial neoplasia and invasive 
cervical cancer. Human papilloma virus infection has gradually been considered 
a necessary prerequisite for cervical carcinoma. 
Numerous other risk factors have been proposed including young age at first 
intercourse (less than 16 years), sexual promiscuity in both males and females, 
cigarette smoking, high parity and lower socioeconomic status with a few 
studies relating significant racial difference among different ethnic and 
socioeconomic groups which probably reflects the access to health care 
facilities and screening program, the impact of which is more pronounced with 
increasing age. AIDS and iatrogenic immunosuppression in transplant patients 
is also associated with cervical cancer. Several studies also point to the use of 
oral contraceptives and subsequent adenocarcinoma of cervix. 
Clinical Presentation:  
In populations where screening penetrance is more the proportion of cases 
detected by cytology examination of cervical smear is comparatively more and 
diagnosis is at an earlier age. The most common presentation in symptomatic 
patients is abnormal bleeding per vagina which may be present for a long time 
before it comes to attention. In a review of cervical cancer cases by Pretorius et 
al. 56% of all cases presented with abnormal vaginal bleeding, 28% had an 
abnormal pap smear, 9% presented with pain, 4% had vaginal discharge and 3% 
with other symptoms [2]. The presence of a negative pap smear in a screening 
[10] 
 
program, but in presence of suspicious clinical presentation, should be 
investigated further as the false negativity rate of pap smear in a case of 
invasive carcinoma may be as high as 50% [3]. 
Pathogenesis of Cervical cancer 
Human papilloma virus is one of the most frequently sexually transmitted 
infections, it is associated with condyloma acuminata, anogenital (cervix, 
vagina and anal) squamous intraepithelial lesions and their progression to 
malignancy, and head and neck cancer. A study by Richart and Barron 
suggested that invasive squamous cell carcinoma was the result of progressive 
intraepithelial dysplastic change. HPV genotypes can be broadly classified into 
“high-risk” which includes types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 
and 68 and “low-risk” including types 6, 11, 40, 42, 43, 44, 53, 54, 61, 72, 73 
and 81. Types 16 and 18 are the most commonly isolated HPV types in cervical 
cancer with type 16 found in approximately 50%of patients [4]. The Viral 
genome codes for six early (E) proteins which are associated with viral gene 
regulation and cell transformation, there are other two late (L) proteins which 
form the shell of the virus, and a region containing  regulatory DNA sequences 
[5,6]. The most important HPV proteins implicated in malignancy are E6 and 
E7. Their action is exerted through interaction with p53 and Rb gene. In a 
normal cell p53 regulates apoptosis and cell cycle, when it is degraded by E-6 
associated protein it results in loss of cell cycle control and loss of apoptosis 
[11] 
 
leading loss of control on proliferation of cells harbouring mutations resulting in 
accumulation of mutations. Same way Rb gene inactivates E2F transcription 
factor by forming E2F/Rb protein complex. When E7 interacts with this 
complex it releases E2F this allows uncontrolled continuation of cell cycle and 
further accumulation of mutations. 
HPV infection is transient in most of the women. Acute infection with HPV is 
latent and characterized by nuclear enlargement, multinucleation, 
hyperchromasia, and perinuclear cytoplasmic clearing (halos) also called as 
koilocytic atypia [7]. Neoplastic transformation occurs when the HPV genome 
integrates with host DNA which usually is seen in high risk HPV. 
 Historically the changes in cervical epithelial cells were described by terms like 
mild, moderate and severe dysplasia which were replaced by CIN 1,2,3 which is 
a histologic diagnosis signifying presence of mitosis, immature cells in lower 
third, lower and middle third and involvement upto upper third. In addition, 
LSIL and HSIL are also used by some to describe histologic results although 
this terminology was originally intended for cytology. For histology, LSIL is 
equivalent to CIN1 and other abnormalities defined above, HSIL comprises 
either CIN 2 or 3.   
 
 
[12] 
 
Histologic Types 
Squamous cell carcinoma 
Invasive cervical carcinoma arises from high-grade dysplasia, which may have 
a long latent period of up to 10 years before invasive carcinoma develops 
[8].The incidence of invasive squamous cell carcinoma developing so is about 
34% over a period of 10 years [9]. Invasive carcinomaof cervix develops most 
often after the age of 40 years [10], although younger women may be affected. 
Invasive squamous carcinomas are classified as keratinizing or non keratinizing, 
although this classification has no prognostic significance. Keratinizing 
squamous carcinoma displays classical keratin pearl formation. Nonkeratinizing 
squamous carcinoma has irregular nests of cells that may display abundant 
eosinophilic cytoplasm with intercellular bridges but do not contain keratin 
pearls. Some squamous carcinomas are composed of smaller cells without 
evidence of neuroendocrine differentiation; these neoplasms are classified as 
small cell squamous carcinoma and generally thought to have poorer prognosis 
compared to large cell carcinoma. 
Adenocarcinoma 
Adenocarcinoma represents about 20% to 25% of cervical cancers in various 
studies. In a study by Ursin et al. oral contraceptive use has been implicated in 
the increase in adenocarcinomas in women younger than 35 years of age [11]. A 
[13] 
 
Canadian study reported presence of HPV in about 70% of cases (53 of 77) with 
HPV 16 the predominant type [12]. The incidence of human papilloma virus 
infection in adenocarcinoma of cervix is generally less than that in squamous 
cell carcinoma. Adenocarcinoma is generally regarded as being more radio-
resistant than squamous carcinoma. In the Italian randomized study comparing 
radical surgery versus radiation therapy for stages IB to IIA cervical cancer, 46 
of 343 patients (13.4%) had adenocarcinoma [13]. Surgery and radiation 
therapy were found to be identical in terms of 5-year survival and disease-free 
survival rates for the entire group, but in the subgroup of patients with 
adenocarcinoma, surgery was significantly better in terms of both overall 
survival (79% vs. 59%, p = 0.05) and disease-free survival rates (66% vs. 47%, 
p = 0.02). 
Adenosquamous Carcinoma 
Adenosquamous carcinoma may form approximately 20% to 30% of all 
adenocarcinomas  of the cervix. Most studies report a poorer outcome. In one of 
the largest series of surgically staged IB cases by Helm et al. [14], 38 patients 
with adenosquamous carcinomas were matched and compared with patients 
with other histologic subtypes of adenocarcinoma. Overall 5-year survival and 
disease-free survival for the matched adenosquamous and adenocarcinomas 
were not significantly different (83% vs. 90% and 78% vs. 81%, respectively), 
however the mean time to recurrence was significantly shorter in the 
[14] 
 
adenosquamous group: 11 versus 32 months (p = 0.003). Similar findings were 
also confirmed in the M.D. Anderson Cancer Centre series comparing 29 
patients with stage IB1 adenosquamous carcinoma with 97 patients with stage 
IB1 adenocarcinoma of the cervix undergoing radical hysterectomy. There was 
no difference in recurrence rates between the two histologic groups, but the time 
to recurrence was shorter for patients with adenosquamous carcinoma (7.9 
months vs. 15 months; p = 0.01) [15]. 
Glassy Cell Carcinoma 
First defined by Glucksman and Cherry in 1956, “glassy cell” carcinoma of the 
cervix was described as a poorly differentiated adenosquamous carcinoma, 
microscopically the cells had moderate amount of cytoplasm and a typical 
“ground glass” appearance. Survival was poor, regardless of the mode of 
therapy. Subsequently, Tamimi et al. concluded that the poor prognosis ascribed 
to the classically defined glassy cell carcinoma also holds true for large-cell 
undifferentiated cervical cancers [16]. 
Adenoma Malignum 
First used by Gusserow in 1870 to describe a very highly differentiated 
adenocarcinoma. McKelvey and Goodlin reported five cases, four of which 
succumbed to disease within 4 years of presentation [17]. In 1975, in a report by 
Silverberg and Hurt, five cases were treated and four of the five were long-term 
[15] 
 
survivors and authors suggested that the cancer was no more malignant than the 
usual adenocarcinoma counterpart. These tumours form a minority of all the 
cervical carcinomas and occur in slightly elderly population. 
Adenoid Cystic Carcinoma 
Adenoid cystic carcinoma is a rare tumour. In a report by Musa et al. the sites of 
origin of these tumours in the female genital tract were Bartholin's gland, the 
endometrium, and the cervix [18]. Etiology of these tumours is unresolved. 
Overall survival is poor. Prempree et al. in a review of literature, reported a 3- 
to 5-year survival rate of only 56.3% (9 of 16) for patients with stage I disease, 
regardless of the type of treatment. The survival rate for stage II disease was 
27.3% (3 of 11), and no patient with stage III or IV disease survived 3-5 years. 
Lung metastases were common site of distant spread, whereas spread locally 
was by direct tissue invasion and perineural infiltration. 
Adenoid Basal Carcinoma 
This is a rare tumour with an excellent prognosis. Most adenoid basal 
carcinomas have coexistent in situ or invasive squamous carcinoma, and almost 
half have coexistent in situ or invasive adenocarcinoma. The tumour is almost 
invariably confined to the cervix, and in a review of 26 cases reported in the 
literature, only one died of disease due to lung metastases [19]. Tumour 
[16] 
 
invasion is usually superficial, and simple or radical hysterectomy without 
lymphadenectomy is a reasonable treatment option. 
Clear Cell Adenocarcinoma 
The tumourhas a bimodal peak, first in those younger than 24 years and those 
older than 45 years [20]. The former are related to in utero diethylstilbestrol 
exposure, but even in these young women, there is no history of hormone 
exposure in approximately 25% of cases, the prognosis is comparable to that of 
other adenocarcinomas [20,21]. 
Villoglandular Papillary Adenocarcinoma 
An uncommon type of tumour, occurs in younger women and has a more 
favourable prognosis. In a report by Young and Scully describing 13 cases, the 
patients' ages ranged from 23 to 54 years (average 33 years). Treatment was 
done by cone biopsy for early stage and radical hysterectomy and pelvic 
lymphadenectomy in others. With follow-up of 2 to 14 years, no recurrences 
were seen. 
Small-Cell Carcinoma 
Small-cell cancers are rare representing 0.5% to 5% of all invasive cervical 
cancers. In a study of 2,201 invasive cervical cancers at the University of 
Kentucky Medical Centre, Van Nagell et al. noted 25 cases (1.1%) of small-cell 
carcinoma. 33% of these stained positively for the neuroendocrine markers 
[17] 
 
(neuron-specific enolase and chromogranin), others stained only for epithelial 
markers such as cytokeratin and epithelial membrane antigen. In general these 
tumours have a higher frequency of lymph-vascular space invasion, 
significantly higher recurrence, metastasis to extrapelvic sites, and a lower 
survival rate overall. 
A later study of SEER data from 1977 to 2003, 0.9% patients were diagnosed 
with small-cell carcinoma of the cervix, five year survival for small-cell 
carcinoma (35.7%) was worse compared with squamous cell carcinoma (60.5%) 
and adenocarcinoma (69.7%) with a predilection for nodal and distant 
metastases, the poor survival was independent of stage and nodal status. The 
group at the Chang Gung Memorial Hospital in Taiwan administered adjuvant 
chemotherapy to 23 consecutive patients with stage IB to II small-cell cervical 
cancer who had been treated primarily with radical hysterectomy. Ten of 14 
patients (71.4%) who received a combination of vincristine, doxorubicin, and 
cyclophosphamide alternating with cisplatin and etoposide had no evidence of 
disease during a median follow-up of 41 months, whereas only 3 of 9 (33.3%) 
who received cisplatin, vinblastine and bleomycin (PVB) survived. The survival 
rate was 70% for patients with negative lymph nodes and 35% for those with 
positive nodes (p = 0.05). All patients who died of disease had extrapelvic 
metastases [22]. 
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Papillary Serous Carcinoma 
Pathologically tumour resembles papillary serous carcinoma of ovary. In a 
study by Zhou and colleagues 17 cases were reported. Two peaks were 
observed one occurring before the age of 40 years and the second peak after 65 
years. The outcome for patients with stage I tumours was similar to that of 
patients with cervical adenocarcinomas of the usual type however, patients with 
advanced disease were more likely to have rapidly fatal outcome with 
widespread metastasis. 
Sarcoma 
In a literature review Rotmensch et al. identified 105 reported cases of cervical 
sarcomas. A variety of treatment strategies had been used in the management of 
cervical sarcomas, and generally the overall prognosis was poor [23]. 
Sarcoma Botryoides 
In 1988 a report by Daya and Scully [24] reviewed 13 cases whose ages ranged 
from 12 to 26 years, with a mean of 18 years. All had polypoid tumour  and 
presented with vaginal bleeding with or without tumour protruding from the 
introitus. The patients were treated with operative procedures ranging from 
cervical polypectomy to hysterectomy with pelvic and paraaortic node 
dissection with and without chemotherapy. Twelve of the 13 patients (92%) 
were alive and well 1 to 8 years after surgery. 
[19] 
 
Malignant Mixed Müllerian Tumour 
A rare subtype of cervical carcinoma. Most patients present with abnormal 
vaginal bleeding. Treatment is by radical hysterectomy with or without 
radiotherapy. Using such an approach in a report of five cases from Iowa, 
Sharma et al. reported survival of these patients, all were alive and free of 
disease at 28, 35, 42, and 65 months, respectively [25]. 
Lymphoma 
Cervical lymphomas are rare, in a study by armed forces institute of pathology 
these constituted about 0.06% of all lymphomas. Presentation is like any other 
cervical cancer but histologic diagnosis is difficult. Harris and Scully reported 
that only 15 of 25 cases (55%) referred for consultation were correctly 
diagnosed by the referring pathologist. Komaki et al. emphasized the 
importance of distinguishing malignant lymphoma from undifferentiated 
carcinoma or sarcoma because cervical lymphoma can be successfully treated in 
spite of locally advanced disease [26]. 
Verrucous Carcinoma 
Usually a slow-growing, locally aggressive, papillomatous lesion. This was first 
reported in the cervix in 1972.In a literature review in 1988, by Crowther et al., 
suggested that some of these should be considered papillomas that had 
undergone malignant change. Radical surgery is the mainstay of treatment. 
[20] 
 
Melanoma 
Malignant melanoma of the cervix is a rare entity. These tumours have, in 
general, been reported to occur in the seventh and eighth decades and most 
lesions present with abnormal vaginal bleeding. Treatment is usually radical 
hysterectomy with or without pelvic lymphadenectomy. Adjuvant radiation may 
improve local control if the surgical margins are close. The 5-year survival rate 
is poor, not exceeding 40% for stage I disease and reaching only 14% in stage II 
[27,28]. 
Metastatic Carcinoma 
Metastasis of malignant epithelial tumours to the uterine cervix is a rare 
occurrence. A study by Lemoine and Hall reportedonly 33 acceptable cases 
from 1919 to 1984. Primary sites of disease included stomach, ovary, colon, 
breast, kidney, renal pelvis, carcinoid, and pancreas. 
Patterns of Spread 
Direct infiltration: Malignant cells penetrate the basement membrane 
progressively infiltrating the underlying stroma and tissues in continuity. 
Lymphatic Spread: Cervical cancer can spread to all pelvic node groups, 
although the obturator nodes are most frequently involved. The parametrial 
nodes, common iliac and paraaortic nodes may be directly involved by aberrant 
pathways, however, generally the lymph node spread in cervical cancer is in an 
[21] 
 
orderly fashion from the nodes on the pelvic sidewall to the common iliac and 
then the paraaortic group. From the paraaortic nodes, spread can occasionally 
occur through the thoracic duct to the left scalene nodes [29]. 
The concept of sentinel node identification for cervical cancer was first 
introduced by Dargent in 2000 [30]. Several authors have subsequently  
identified sentinel nodes in 70% to 100% of patients. Sentinel nodes have 
usually been located in the hypogastric, external iliac, obturator, common iliac 
and paraaortic regions and sometimes in unusual location like in the left groin 
[31]. 
Burghardt and Girardi [32] proposed the mechanism of discontinuous 
paramtrial involvement by tumour emboli held up in lymphatic vessels in 
parametria grow to become foci of discontinuous parametrial involvement. 
Ovarian involvement by cervical cancer is rare but most likely occurs through 
the lymphatic connection between the uterus and the adnexal structures. In a 
study of patients with clinical stage IB cervical cancer, the GOG reported 
ovarian spread in four of 770 patients (0.5%) with squamous carcinoma and in 
two of 121 patients (1.7%) with adenocarcinoma. All patients with ovarian 
metastases had other evidence of extracervical spread [33]. 
[22] 
 
Hematogenous Spread: Although spread to virtually all parts of the body has 
been reported, the most common organs for hematogenous spread are the lungs, 
liver, and bone. 
Overview of management of early stage disease (FIGO IA, IB, IIA) 
Early stage disease treatment decision is based on a variety of factors including 
informed decision making between patient and the treating physician, desired 
side effect profile, health concerns of the patient and future fertility concerns. 
Fertility sparing surgery 
Microinvasive disease  
 Women with stage IA1 disease without lymphovascular space involvement 
(LVSI) are candidates for treatment with conization or simple hysterectomy, a 
number of Studies show that recurrence occurs in 3% or fewer of these patients 
[34,35,36]. 
A United States national cancer database study (n=1409) of women age less 
than40 years with stage IA1 cervical cancer found no significant difference in 
five-year survival between those who underwent conization versus 
hysterectomy (98 versus 99 %); data regarding LVSI were not available [37]. 
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Vaginal Radical Trachelectomy 
The vaginal radical trachelectomy procedure was developed by the late 
Professor Daniel Dargent from Lyon, France at the end of the 1980s. Suitable 
candidates should be desirous to preserve fertility, having age less than 40 
years, Stage IA1 with vascular space invasion, IA2 or IB1, lesion size less than 
2 to 2.5 cm, with limited endocervical extension as assessed by colposcopy and 
magnetic resonance imaging, squamous carcinoma or adenocarcinoma histology 
with no evidence of lymph node metastasis. 
Abdominal Radical Trachelectomy  
The abdominal radical trachelectomy procedurewas developed by Smith et al in 
1997 [38].  
Radical Hysterectomy 
Advantages of surgery over primary chemoradiotherapy for young women are: 
1. The ovaries can be left intact, and  
2. The sexually active patient may be left with a more functional vagina, 
3.  If the need for adjuvant RT is anticipated, the ovaries can be transposed out 
of the RT field.  
4. Resection of bulky metastatic lymph nodes may be of therapeutic benefit.  
[24] 
 
On the other hand, if a primary surgical approach is chosen and adjuvant 
chemoradiotherapy is required, there may be additional morbidity from this 
multimodality approach, as compared to definitive chemoradiotherapy or 
definitive radiotherapy. 
Types of Radical Hysterectomy 
In 1974, Piver et al. [39] described the following five types of hysterectomies: 
Type I  Extrafascial Hysterectomy: This is a simple hysterectomy and is suitable 
for stage IA1 cervical carcinoma. 
Type II Modified Radical Hysterectomy: This is basically the hysterectomy 
described by Ernst Wertheim [40]. The uterine artery is ligated where it crosses 
the ureter, and the medial half of the cardinal ligaments and proximal 
uterosacral ligaments are resected with specimen. Removal of upper 1/3rd 
vagina as described by Piver et al. is usually not necessary. Wertheim described 
removal of involved enlarged nodes rather than systematic pelvic 
lymphadenectomy. The modified radical hysterectomy is appropriate for stage 
IA2 cervical cancer. 
Type III Radical Hysterectomy: Performed for stage IB cervical cancer, this 
operation was originally described by Meigs in 1944 [41]. The uterine artery is 
ligated at its origin from the superior vesicle or internal iliac artery, allowing 
removal of the entire width of the cardinal ligaments. Piver et al. described 
[25] 
 
excision of the uterosacral ligaments at their sacral attachments and resection of 
the upper half of the vagina. 
Type IV Extended Radical Hysterectomy: This differs from the type III 
operation in three aspects: (i) The ureter is completely dissected from the 
vesicouterine ligament, (ii) the superior vesicle artery is sacrificed, and (iii) 
three-fourths of the vagina is excised. The risk of ureteric fistula is increased 
with this procedure. Piver et al. used this for selected small central recurrences 
after radiation therapy. 
Type V  Partial Exenteration: This procedure was intended for removal of a 
central recurrence involving a portion of the distal ureter or bladder. The 
relevant organ was partially excised and the ureter reimplanted into the bladder. 
This procedure may occasionally performed in primary setting if cancer is 
found to be unexpectedly encasing the distal ureter at the time of radical 
hysterectomy.  
A new classification for radical hysterectomy was described by Shingo Fuji in 
February 2007 [42]. The classification is based only on the lateral extent of the 
resection. Four basic types are described, A-D, adding when necessary a few 
subtypes that consider nerve preservation and paracervical lymphadenectomy. 
Lymph node dissection is considered separately, and four levels 1,2,3,4 are 
defined according to the corresponding arterial anatomy and the radicality of the 
procedure. 
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Choice of hysterectomy: Type II Versus Type III 
The therapeutic efficacy of a type II radical hysterectomy appears comparable to 
that of a type III procedure for stage IB and IIA cervical cancer, but with lower 
morbidity. A randomized trial compared type II (modified radical hysterectomy) 
and type III (radical hysterectomy) procedures in patients with stage IB or IIA 
disease [43]. The type II operation was associated with a shorter mean operative 
time (135 versus 180 minutes), less late urologic morbidity (13 versus 28 %), 
and similar recurrence rates (24 versus 26%), cause-specific mortality (18 
versus 20 %), five year overall survival (OS, 81 versus 77 %) and five year 
disease-free survival (DFS) (75 versus 73 %). Thus, the choice of procedure 
depends on margins of resection with type II procedure being as good as type III 
procedure provided safe margins can be obtained.  
A number of studies have reported that a minimally invasive radical 
hysterectomy has a definitive perioperative advantages (decreased blood loss, 
shorter hospitalization, faster recovery, better cosmetic results) compared with 
an abdominal radical hysterectomy [44, 45, 46, 47]. However, there are no 
appropriately powered randomized controlled trials to confirm whether long-
term patient survival is equivalent for the two surgical approaches. 
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No residue after radical hysterectomy 
In cases where presumably diagnostic excision biopsy resulted in complete 
removal of tumour and subsequent radical hysterectomy specimen did not 
reveal any tumour residue, these patients have an excellent prognosis. In a 
retrospective review of 594 patients with invasive cervical cancer, 29 % of 
patients, all with stage IA1 to IB1 disease, had no residual tumour in the 
pathology specimen [48]. These women have an excellent prognosis with 
radical hysterectomy and lymph node dissection only. 
Lymph node sampling 
 A primary surgical approach to treatment of cervical cancer allows resection of 
bulky lymph node metastases, which may be of therapeutic benefit. For 
paraaortic node metastases, a large retrospective study found that survival was 
improved in women who underwent lymph node sampling (n = 555) compared 
with radiographic evaluation (n = 130) [49]. All patients had FIGO stage IIB 
through IVA disease with no evidence of paraaortic lymph node metastases and 
were subsequently treated with cisplatin based chemoradiation. Patients who 
had lymphadenectomy had a better prognosis than those who were evaluated 
radiographically. Patients with stage III/IV disease had four-year progression-
free survival and overall survival of 49% and 54% for the surgically staged 
patients versus 36% and 40% for the radiographically staged patients. 
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Indications for adjuvant therapy 
High-risk disease  
 Women with one or more of the following findings are considered to be at high 
risk for recurrent disease, and should receive adjuvant therapy following 
hysterectomy [50,51]: 
Positive or close resection margins, 
Positive lymph nodes, 
Microscopic parametrial involvement, 
Although increase in the number of positive nodes increases the risk of 
recurrent disease [52,53], even one microscopically positive node has the same 
recurrence risk as several positive nodes and adjuvant chemoradiotherapy 
should be considered [54]. 
Radiation versus chemoradiotherapy 
The superiority of concomitant chemoradiotherapy over adjuvant radiotherapy 
(RT) alone was initially shown in a trial that randomly assigned 268 women 
undergoing hysterectomy for high-risk but localized cervical cancer to 
radiotherapy (49.3 Gy in 29 fractions to a standard pelvic field) with or without 
chemotherapy (four cycles of cisplatin 70 mg/m2 on day 1, plus 5-fluorouracil 
[5-FU] 1000 mg/m2 per day by continuous infusion for four days, every three 
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weeks) [50]. The first and second courses were administered concurrent with 
radiotherapy. The use of chemotherapy was associated with a significantly 
better four year overall survival (81 versus 71 %) and progression-free survival 
(PFS, 80 versus 63 %). 
The benefits of chemoradiotherapy over radiotherapy alone were again 
confirmed in a Cochrane meta-analysis of 13 randomized trials comparing 
chemoradiotherapy versus radiotherapy alone in women with FIGO stage IA to 
IVA disease. In this meta-analysis Compared with radiotherapy alone, 
chemoradiotherapy was associated with a significant 19 % reduction in the risk 
of death, which translated into an absolute improvement in five-year overall 
survival from 60 to 66 %. Results from two trials suggested that there was a 
larger benefit by adjuvant chemotherapy after concurrent chemoradiotherapy. 
There was a trend toward greater benefit from chemoradiotherapy in patients 
with lower stage disease. The hazard ratios for overall survival benefit 
translated into absolute five-year survival benefits of 10%, 7%, and 3 % for 
patients with IB/IIA, IIB, and III to IVA disease, respectively. 
Benefits were obtained by using non-platinum as well as platinum based 
chemotherapy concurrently with radiation.  
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Intermediate-risk disease  
The benefit for postoperative radiotherapy in women with factors suggestive of 
intermediate-risk disease was demonstrated in a randomized GOG trial that 
assigned 277 such women to pelvic radiotherrapy (without chemotherapy) or no 
further postoperative treatment. The features that were considered indicative of 
intermediate risk-disease in this study were as follows [56, 57]: 
Large tumour size (>4 cm) [58], 
Deep cervical stromal invasion (to the middle or deep one-third), 
Lymphovascular space invasion, 
Adjuvant RT was associated with a significant improvement in two-year 
recurrence-free survival (88 versus 79 %), and despite early follow-up, a 
significant 36 % reduction in the risk of death [59]. In a later publication with 
10-year median follow-up, a significant benefit was still evident for 
radiotherapy in terms of progression-free survival (hazard ratio [HR] 0.58, 95% 
CI 0.40 to 0.85), but the 30 % reduction in the risk of death was not statistically 
significant (p = 0.07).  
Chemoradiotherapy versus RT in intermediate risk patients 
There are no randomized trials that specifically address the benefit of 
chemoradiotherapy versus RT alone in women with intermediate-risk early 
stage cervical Squamous cell carcinoma. A secondary analysis of the trial (GOG 
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109) of postoperative RT versus chemoradiotherapy in women undergoing 
radical hysterectomy and pelvic LND for stage IA2, IB or IIA cervical cancer 
showed the absolute improvement in five-year survival from the addition of 
chemotherapy to RT appeared to be less for tumours <2 cm (82 versus 77 %, 
difference of 5 %) than for those over 2 cm (77 versus 58 %, difference of 19 
%), and for patients with only one nodal metastasis compared to more than one. 
This data supports the view that smaller tumours derive quantitatively less 
benefit from the addition of chemotherapy to RT. 
Definitive radiotherapy and chemoradiotherapy  
Oncologic outcomes are similar with either definitive radiotherapy (RT) or 
radical surgery with or without postoperative radiotherapy for treatment of early 
stage (stages IA, IB, and IIA) disease. The best available evidence comes from 
the only randomized trial which directly compared hysterectomy plus adjuvant 
RT versus RT alone (without concurrent chemotherapy) in 343 women with 
stage IB1 to IIA disease [61]. Five-year rates of overall survival and DFS were 
identical in both groups (83 and 74 %, respectively). A subsequent analysis 
suggested the superiority of surgery over RT [62]. This retrospective review of 
data on 4885 women with stage IB1 to IIA cervical cancer treated between 1988 
and 2005 and included in the United States SEER (Surveillance, Epidemiology 
and End Results) registry, in multivariate analysis, there was an apparent 
survival benefit for surgery versus RT alone in women with tumours ≤6 cm 
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(relative reduction in mortality with surgery versus RT was 62 and 49 % for 
tumours <4 and between 4 and 6 cm, respectively). However, this study had 
several major limitations. The most obvious limitation is the inherent bias that 
impacts treatment selection (ie, healthier women are more likely to be selected 
for surgery than to radiotherapy). Furthermore, one half of the women in the 
hysterectomy group also received radiotherapy, and comparisons were not made 
between women treated solely with surgery versus radiotherapy. Finally, as with 
the randomized trial described above, the lack of information on use of 
concurrent chemotherapy limits the interpretation of the results with 
radiotherapy. The superiority of concomitant chemoradiotherapy over 
radiotherapy alone in women with both early and locally advanced cervical 
cancer had been shown in at least five controlled trials and a meta-analysis. 
These data have led to the adoption of chemoradiotherapy as the preferred 
approach whenever RT is administered for the treatment of women with 
cervical cancer, over a broad spectrum of disease stages.  
Radiotherapy Techniques 
The two main methods of radiotherapy delivery are external photon beam and 
brachytherapy, brachytherapy in turn can be delivered using an intracavitary 
approach or via an interstitial approach. Brachytherapy alone is adequate 
treatment for stage IA1 disease, external beam RT is generally added to 
brachytherapy to improve pelvic control with more advanced disease. 
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Intracavitary brachytherapy is the most widely used technique while interstitial 
brachytherapy is typically considered for women whose disease cannot be 
optimally encompassed by intracavitary application. In a retrospective series 
comparing outcomes in 61 patients with stage II (bulky), III, or IVA cervical 
cancer treated with combined external beam RT and intracavitary brachytherapy 
versus 70 similarly staged women treated with external beam radiotherrapy and 
interstitial brachytherapy [63]. Inferior outcomes were found in women treated 
with interstitial therapy in terms of five-year DFS (21 versus 50 % p = 0.01) and 
local-regional control (32 versus 61 %, p = 0.01). Morbidity was same in both 
the groups [63]. Thus, interstitial brachytherapy should be used only in select 
cases in which the use of intracavitary radiotherapy is precluded. 
HDR brachytherapy provides the significant advantage of eliminating exposure 
of medical personnel to radiation, a shorter treatment period, and the possibility 
of ambulatory treatment. In at least three randomized trials in women with 
cervical cancer, HDR was comparable to LDR brachytherapy in terms of 
oncologic outcomes and complication rates [64,65,66]. The use of external 
beam RT prior to brachytherapy offers several advantages by decreasing size of 
bulky endocervical tumours allowing more optimal coverage by the 
intracavitary dose distribution, while shrinking bulky ectocervical disease 
improves tumour geometry and therefore optimal brachytherapy placement. The 
treatment volume for women undergoing adjuvant external beam RT typically 
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involves the whole pelvis, with larger portals required for higher stage (ie, IIA) 
disease. Extended field RT, in which the treatment portal is extended to the 
paraaortic region, is typically considered for women who are known to or 
suspected of harbouring paraaortic lymph node metastases, typically those with 
more advanced stage disease. 
The use of IMRT and brachytherapy have been compared with conventional 
radiotherapy and brachytherapy, the results consistently show reduction in 
toxicity and radiation morbidity with equivalent oncologic control rates. 
Role Of Ovarian Transposition  
 Women who undergo pelvic radiotherapy will develop premature ovarian 
failure as a side effect of radiotherapy. In an attempt to prevent this ovarian 
transposition out of the field of radiation has been tried but without much 
success. The benefits are inconsistent partly due to scatter radiation and also due 
to theoretical possibility of disease recurrence in the region where ovaries are 
shielded.  
Role Of Postchemoradiotherapy Extrafascial Hysterectomy 
Extrafascial hysterectomy confers little, if any, overall survival benefit. The 
benefit of adjuvant extrafascial hysterectomy after radiotherapy alone was 
studied in a GOG trial in which 256 patients with tumours measuring more than 
4 cm were randomly assigned to radiotherapy alone or radiotherapy followed by 
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surgery [67]. There was a lower cumulative incidence of local relapse in the 
surgery group (at five-years, 14 versus 27 %), but not survival benefit. 
Surgery Versus Chemoradiotherapy 
As discussed above, definitive RT and radical surgery are both accepted 
treatments of early stage cervical cancer, since oncologic outcomes are similar. 
Therefore, the decision to proceed with one versus the other is based on other 
factors, such as childbearing plans, comorbidities, physician and patient 
preference, and quality of life (QOL) issues. 
In general, QOL measures in cancer survivors appear to be higher following 
surgery than RT; however, it is difficult to draw firm conclusions from the 
available data due to methodological differences [68]. Ovarian function is more 
likely to be preserved with surgery than RT, providing a benefit to 
premenopausal patients. Primary surgery also allows for resection of bulky LN 
metastases, which may be of therapeutic benefit, through staging lymph node 
dissection, and it enables the selection of patients for postoperative 
chemoradiotherapy based upon histopathological review of surgical specimens. 
Sexual function and psychosocial well-being 
 Both hysterectomy and radiotherapy can lead to changes such as vaginal 
shortening and decreased vaginal lubrication, which adversely influence sexual 
function, overall QOL, and psychosocial well-being following treatment. The 
[36] 
 
reported frequency with which these changes occur is quite variable. Vaginal 
changes after RT include foreshortening, stenosis, and decreased lubrication. 
These physical changes impact sexual function because they can result in 
dyspareunia, and influence sexual satisfaction, the ability to have an orgasm, 
and coital frequency. 
The separate contribution of deficits related to surgery or radiotherapy was 
addressed in a retrospective comparison of 114 women who were interviewed 
five years after completing treatment for cervical cancer with either surgery (n = 
37) or RT (n = 37); a separate control group consisted of age- and race-matched 
women with no history of cervical cancer [69]. Compared to surgically treated 
women and controls, irradiated women had significantly worse scores on 
standardized questionnaires measuring health-related quality of life (physical 
and mental health), psychosocial distress, and sexual functioning. In contrast, 
there were no significant differences in any of these measures when women 
undergoing surgery for cervical cancer were compared to controls.  
Prognosis 
 The major prognostic factors affecting survival among women with cervical 
SCC are stage, nodal status, tumour volume, depth of cervical stromal invasion, 
lymphovascular space invasion (LVSI), and to a lesser extent, histologic type 
and grade. Disease stage is the most important prognostic factor, followed by 
LN status. After radical hysterectomy and LND, women with stage IB or IIA 
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disease, who have negative pelvic lymph nodes have a five-year survival of 88 
to 96 %, compared to 64 to 74 % for those with similar stage disease and pelvic 
nodal metastasis. Outcomes are worse for women with involved paraaortic 
nodes. Among patients who have undergone surgical staging the number of 
involved lymph nodes also influences prognosis, in one report by Tanaka et al. 
five-year survival rates for patients with one, two, three to four, and five or 
more positive lymph nodes were 62, 36, 20 and 0 %, respectively [70]. The 
prognostic significance of pelvic LN micrometastases in women with early 
stage disease is unclear [71, 72, 73, 74]. 
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Results 
Total patient records studied for the  purpose of this study were 300, out of 
which 153 records were found suitable for the purpose of inclusion in study 
group and 92 were found eligible for inclusion in the control group. 
Age distribution 
The distribution of cases in study group is as follows: 
Age (years) Study group % of total Control group % of total 
20-39 83 54.2 % 20 21.7% 
40-59 67 43.8% 54 58.7% 
>60 3   2.0% 18 19.5% 
                              
Total 
153 100% 92 100% 
 
 
 
* Representation of absolute numbers 
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Presentation 
Presenting complaints were as follows: 
 
Complaints Study group %  Control 
group 
% Total % 
Bleeding PV 81 52.9% 48 52.2% 52.6% 
Discharge PV 39 25.5% 38 41.3% 31.4% 
Bleed with Discharge 
PV 
30 19.6% 3 3.3% 13.5% 
Pain in abdomen 3 2% 3 3.3% 2.4% 
Total No. 153  92  245 
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Family History of cancer 
Family history of cancer was present in both groups as follows: 
Family History Study Group Control Group Total 
Present 23 12 35 
Absent 130 80 210 
% 15% 13.2% 14.28% 
 
 
The distribution of family history between cases and controls was not different 
statistically (p=0.667)  
Addictions  
Addictions were present as in the following: 
Addictions Study Group Control Group Total 
Present 11 17 28 
Absent 142 75 217 
% 7.2% 18.5% 11.4% 
14% 
86% 
Family History 
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Marriage and age at first sexual exposure  
The age at sexual exposure and marriage was coinciding for all patients. The 
mean age at sexual exposure in study as well as control group was 17 years. 
 
Abortions 
History of abortion was present as follows: 
Abortion Study Group Control Group Total 
Present 23 3 26 
Absent 130 89 210 
% 15% 3.3% 10.61% 
11% 
89% 
Addictions 
Present Absent
[42] 
 
 
Menopausal Status 
The menopausal status between both groups was as follows: 
Menopause Study Group Control Group Total 
Pre 127 52 179 
Post 26 40 66 
%Premenopusal 83% 56.5% 73.06% 
 
 
 
The difference in distribution of pre and post menopausal cases in both the 
groups was statistically significant (p=0.0001). 
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Puerperal sterilization was done in 54.2% of patients in study group and history 
of consanguineous marriage was present in 36% of patients in study group and 
in 20% of patients in control group. 
 
Biopsy 
The distribution of biopsy results was as follows: 
Biopsy Study Group % Control Group % 
Sq. Cell Ca 123 80.4% 82 89% 
AdenoCa 20 13.1% 3 3.3% 
AdenoSq Cell 
Ca 
6 3.9% 2 2.2% 
Poorly 
differentiated 
Ca 
4 2.6% 5 5.4% 
 
 
 
The distribution of pre-treatment histopathology was statistically different 
(p=0.042).  
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The relative distribution of tumour in ecto and endocervix was 88% and 12% in 
study group, whereas 99% tumours in control group were arising from 
ectocervix. 
Similarly, Haemoglobin value in blood was more than 10g% in 125 patients 
(82%)and less than 10 g% in 24 patients (16%),pretreatmentHaemoglobinwas 
not available for 2% of patients in study group. In control group Haemoglobin 
was more than 10 g% in 84 patients (91.3%) ,less than 10 g% in 6 patients 
(6.5%) and in 2.2% the pretreatment Haemoglobin was not available. The 
difference distribution of haemoglobin between cases and controls was not 
statistically significant (p =0.1) 
 
 
86 (56.2%) cases were stage IB and 67 (43.8%) stage IIA in study group 
whereas in control group 28 (30.4%) were stage IB and 64 (69.6%) were stage 
IIA. This distribution of stage IB and II A was found to be statistically different 
between cases and controls (p= 0.0001) 
113 patients (73.9%) were treated with intracavitary application and 40 (26.1%) 
received external beam radiotherapy before surgery in study group, whereas in 
control group 3 patients (3.3%) received external beam radiation, 59 (64.1%) a 
combination of the two and 30 (32.6%) received intracavitary application. 
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Mean blood loss in surgery group was 445 ml and 73 patients did not require 
transfusion after surgery, mean blood volume transfused was approximately 200 
ml. 
 
Residue 
Post neoadjuvant radiotherapy, 47 patients did not have any residue whereas 
106 patients had a residue amongst 153 patients in study group. 
 
Mean nodal yield was 13 nodes, the incidence of nodal positivity in the whole 
study group as in final post-operative histopathology report was 24 (15.7%). 
Meananterior vaginal cuff margin was 1.33cms and posterior vaginal cuff 
margin was 1.9cms. Incidence of microscopically positive margin was 1.3% (2) 
in the entire study group, 1 (0.7%) margin showed moderate dysplasia. 
Mean right parametrial margin was 1.43cms and mean left parametrial margin 
was 1.44cms. 
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Disease Status 
During the entire period of follow up the following observations were made: 
Status No. of patients Percentage 
No recurrence 124 81% 
Local recurrence 13 8.5% 
Regional recurrence 1 0.7% 
Distant recurrence 13 8.5% 
Unknown 2 1.3% 
 
 
For the purpose of calculating disease free survival patients with unknown 
status were included in no recurrence group and 82.4% patients (126/153) were 
disease free at the time of this analysis. 
After a follow up of 8-12 years the mean disease free survival in the study 
group was 85.34 months (approximately 7.11 years) and disease free survival in 
the control group was 92.18 months (7.7 years). 
Univariate Analysis Of  Study Group (by Chi square test) 
Disease free survival was as follows: 
DFS 5 year 10 year 
Study Group 85% 75% 
Control Group 91% 78% 
P value 0.188; Not Significant 
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Effect of Haemoglobin was as follows: 
DFS 5 year 10 year 
< 10 g% 87% 82% 
>10 g% 85% 74% 
P value 0.925; Not Significant 
 
Effect of Menopausal status was as follows: 
DFS 5 year 10 year 
Premenopausal 87% 76% 
Postmenopausal 79% 74% 
P value 0.383 ; Not Significant 
 
Effect of histology was as follows: 
DFS 5 year 10 year 
Sq Cell Ca 85% 76% 
AdenoCa 85% 70% 
AdenoSqCa 83% 83% 
Poorly Diff Ca 100% 100/% 
P value overall 0.841 ; Not Significant 
 
The effect of stage was as follows: 
DFS 5 year 10 year 
Stage IB 91% 85% 
Stage IIA 77% 64% 
P Value 0.021 Significant 
 
The effect of EBRT Vs. ICA was as follows: 
DFS 5 year 10 year 
EBRT 78% 73% 
ICA 88% 76% 
P Value 0.240  Not Significant 
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The effect of residue in hysterectomy specimen was as follows: 
DFS 5 year 10 year 
No residue 98% 78% 
Residue 80% 72% 
P Value 0.003     Significant 
 
The effect of finding a positive node in final histopathology is as follows: 
DFS 5 year 10 year 
Negative Node  88% 78% 
Positive node 69% 62% 
P Value 0.015     Significant 
 
Effect of resected edge positivity in final histopathology is as follows: 
DFS 5 year 10 year 
Negative RE 88% 78% 
Positive RE 20% 00% 
P Value 0.0001     Significant 
 
Univariate Analysis of control group (by Chi Square Test): 
The effect of haemoglobin was as follows: 
DFS 5 year 10 year 
< 10 g% 83% 33% 
>10 g% 91% 81% 
P value 0.017 ; Significant 
 
The effect of stage on treatment result was as follows: 
DFS 5 year 10 year 
Stage IB 96% 61% 
Stage IIA 88% 83% 
P Value 0.293  Not significant 
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Effect of Menopausal status was as follows: 
DFS 5 year 10 year 
Premenopausal 96% 79% 
Postmenopausal 84% 80% 
P value 0.106 ; Not Significant 
 
Effect of histology was as follows: 
DFS 5 year 10 year 
Sq Cell Ca 91% 80% 
AdenoCa 67% <33% 
AdenoSqCa 100% 100% 
Poorly Diff Ca 100% 0.71% 
P value overall 0.076; Not Significant 
P value for SCC 
VsAdeno CA 
0.013 ; Significant 
 
COX REGRESSION ANALYSIS 
Variable Significance 95% CI Lower 95% CI Upper 
Case 0.078 0.929 3.98 
Menopausal status 0.092 0.903 3.82 
Stage 0.02 1.143 4.635 
Haemoglobin 0.464 - - 
 
Hence on multivariate analysis only stage was a significant predictor of disease 
free survival. 
Complications 
Early complications unique to study group were: 
Complications Frequency Percentage 
No complications 139 90.8% 
High Residual volume 11 7.2% 
Lower limb edema 1 0.7% 
Bleeding 2 1.3% 
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Late complications unique to study group were: 
Complications Frequency Percentage 
No complications 142 92.8% 
Incisional hernia 7 4.6% 
Lower limb oedema 1 0.7% 
SAIO 1 0.7% 
Radiation proctitis 1 0.7% 
Perforation 1 0.7% 
 
Late complications unique to control group were: 
Complications Frequency Percentage 
No complications 34 37% 
Adhesive Vaginitis 38 41.3% 
Haematuria 3 3.3% 
Proctitis 3 3.3% 
Haematuria with Adh Vaginitis  6 6.5% 
Lower Limb Oedema 2 2.2% 
Proctitis with Adh Vaginitis 1 1.1% 
AdhVag with proctitis and 
cystitis 
1 1.1% 
Unknown 4 4.3% 
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Discussion 
 
Cervical cancer is a common cancer affecting our country and world over, but 
the presentation in our country usually is at a later stage reflecting the lack of 
effective screening and possible social barriers. The burden of such late 
diagnosis is more with our rural population.Women of all ages may be affected 
as in our study the youngest patient was 25 years old, hence age alone should 
never exclude cervical cancer. The presenting complaint is usually abnormal 
bleeding per vagina(53% in our study) and many women present with white 
discharge which may be a nonspecific complaint, women may also present with 
blood mixed discharge and some of these may present with nonspecific 
abdominal pain.  
A family history of cancer (15% in our study) may be present. Carcinoma 
cervix and uterus in maternal relatives was a common association in our study 
population, but its epidemiological significance cannot be commented upon at 
this time. In our study population 11% of patient used chewable form of 
tobacco. Age at marriage and first exposure tosexual experience are almost 
coinciding across both study and control group possibly reflecting our social 
structure and values.A majority of our patients were premenopausal reflecting 
the need of keeping long term toxicities of treatment in view and ovarian 
function preservation when deciding appropriate treatment. Their post treatment 
quality of life should also be a consideration. Impact of histologic type on 
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survival in most of the studies is unclear for adenocarcinoma and squamous cell 
carcinoma. However uncommon histological types like melanoma and small 
cell carcinoma have a worse outcome.  
In our study the disease free survival between both treatment groups was 
statistically not significant. 
The effect of haemoglobin level more than or equal to 10 g% did not have 
appreciable impact on DFS in our study group, but in definitive radiotherapy 
group the DFS was significantly lower if haemoglobin level was less than 10 
g%. 
The impact of menopausal status on treatment outcome (DFS) was not 
significant statistically in both study and control group. 
The effect of histology on DFS was overall not significant in our study group as 
well as control group, however DFS of adenocarcinoma treated by definitive 
radiotherapy was significantly lower than DFS obtained for Squamous 
counterpart. 
The effect of stage (IB and IIA) was not statistically significant in control group 
however, the difference was significant in study group. 
In the study group, advantage from use of both the treatment modalities (EBRT 
and ICA) was similar as regards to DFS. Presence of residue in cervix on final 
pathologic examination was associated with significantly reduced DFS when 
compared to no residue on final pathologic examination. Similarly, finding a 
positive node on final pathologic examination was associated with significantly 
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reduced DFS. Positive resection margin similarly was associated with a 
significantly reduced DFS. 
On cox regression analysis, only stage at presentation was a significant 
determinant of DFS with the same being shorter in stage IIA compared with IB. 
Complications between the two arms were different, about 91% of patients in 
study group were free of early post-operative period complications (Within 30 
days). Most of the early complications were transient. Similarly about 93% 
patients were free of late complications in study group, the most common 
complication being incisional hernia. 
In control group about 37% patients were free of late complications and 
adhesive vaginitis was the most common complication (41.3%) in that group 
followed by radiation cystitis and proctitis. Hence side effect profile of the 
study group appears desirable especially in younger patients. 
A few interesting observations were made during the data collection process: 
 A 45 year lady treated for Squamous cell carcinoma cervix stage IIA treated 
with External beam radiotherapy 40 Gy from 31-01-01 to 27-02-01 followed by 
Wertheim’s hysterectomy with Bilateral pelvic lymphadenectomy on 12-04-01, 
she developed right lung upper lobe and left lung lower lobe metastatic lesions 
which were treated with 4 cycles of Cisplatinum, the lesions completely 
disappeared after 2 cycles and she was progression free till last follow up on 
14/11/07. 
[54] 
 
Another 37 year lady with Squamous cell carcinoma cervix stage IIA treated 
with 40 Gy external beam radiotherapy from 27-06-03 to 23-07-03 followed by 
Wertheim’s Hysterectomy and Bilateral pelvic lymph node dissection on 01-09-
03, a chest radiograph done in November 2011 revealed metastasis in left lower 
lobe, she underwent thoracotomy and R2 resection as R0 resection would have 
required pneumonectomy, she was treated by Cisplatinum 4# till 17/7/07 and 
she survived next two years till July 2009. 
These observations suggest than a few patients with metastatic disease may 
have benefit by aggressive approach at relapse. 
 
 [54] 
 
Conclusion 
 
The results from this study show that disease free survival is similar in both the 
study and control group. The factors tosignificantly affect outcome in univariate 
analysis for study groupwere tumour stage, present of residue after neoadjuvant 
radiation, positive nodal status on final histopathology and positive resection 
margin. In control group haemoglobin value less than 10 g% and 
adenocarcinoma histology were correlating with reduced disease free survival. 
Haemoglobin level did not have a significant impact on disease free survival in 
study group. Menopausal status had no effect in both the groups.  Stage at 
treatment was important in study group whereas there was no difference in 
outcome with stage in control group. In multivariate analysis after balancing 
confounding factors stage had significant impact on disease free survival. 
Complications in both the groups are not comparable as both the treatment 
modalities are different and have complications unique to them, however 
complications likely to reduce quality of life like adhesive vaginitis with vaginal 
shortening, dryness were more with definitive radiotherapy, similarly side 
effects needing evaluation like haematuria and cystitis were more in definitive 
radiation group, which are likely to be a cause of concern to patient. 
In conclusion, the side effect profile should be the directing factor to choice of 
treatment, in our study on univariate analysis patients with adenocarcinoma of 
 [55] 
 
cervix fared significantly worse than their squamous cell counterpart when 
treated by definite radiotherapy (p=0.013). 
So we conclude that, neoadjuvant radiotherapy followed by radical surgery is 
the preferred treatment option for early stage carcinoma of cervix, especially so 
in adenocarcinoma histology where disease free survival is likely to be better 
and in younger patients where quality of sexual life is likely to be better also 
long term side effects of definitive radiation would also be avoided. 
 [56] 
 
Bibliography 
1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of eliminating 
socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 
61:212. 
2. Pretorius R, Semrad N, Watring W, Fotherongham N. Presentation of cervical cancer. 
Gynecol Oncol 1991;42:48-52. 
3. Sasieni PD, Cuzick J, Lynch-Farmery E, the National Co-ordinating Network for Cervical 
Screening Working Group. Estimating the efficacy of screening by auditing smear histories of 
women with and without cervical cancer. Br J Cancer 1996;73:1001-1005. 
4. De Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in 
invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 
11:1048. 
5. Palefsky JM, Holly EA. Molecular virology and epidemiology of human papillomavirus and 
cervical cancer. Cancer Epidemiol Biomarkers Prev 1995; 4:415. 
6.  Palefsky JM. Anal human papillomavirus infection and anal cancer in HIV-positive 
individuals: an emerging problem. AIDS 1994; 8:283. 
7. Nucci MR, Crum CP. Redefining early cervical neoplasia: recent progress. Adv Anat Pathol 
2007; 14:1. 
8. Garland SM. Human papillomavirus update with a particular focus on cervical disease. 
Pathology 2002;34:213-224. 
9. Spriggs AI, Boddington MM. Progression and regression of cervical lesions. Review of 
smears from women followed without initial biopsy or treatment. J Clin Pathol 1980;33:517-
522. 
10. Ho GY, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus 
infection in young women. N Engl J Med 1998;338:423-428. 
11. Ursin G, Peters RK, Henderson BE, D'Ablaing G, Munroe KR, Pile MC. Oral contraceptive 
use and adenocarcinoma of the cervix. Lancet 1994;344:1390-1394. 
 [57] 
 
12. Duggan MA, McGregor SE, Benoit JL, Inoue M, Natcon JG, Stuart GCE. The human 
papilloma virus status of invasive cervical adenocarcinoma: a clinico-pathological and 
outcome analysis. Hum Pathol 1995;26:319-325. 
13. Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P, et al. Randomized study of 
radical surgery versus radiotherapy for stage IB-IIa cervical cancer. Lancet 1997;350:535-
540. 
14. Helm CW, Kinney WK, Keeney G, Lawrence WD, Frank TS, Gore H, et al. A matched study 
of surgically treated stage IIB adenosquamous carcinoma and adenocarcinoma of the uterine 
cervix. Int J Gynecol Cancer 1993;3:245-249. 
15. Dos Reis R, Frumovitz M, Milam MR, Capp E, Sun CC, Coleman RL, Ramirez PT. 
Adenosquamous carcinoma versus adenocarcinoma in early-stage cervical cancer patients 
undergoing radical hysterectomy: an outcome analysis. Gynecol Oncol 2007;107:458-463. 
16. Tamimi HK, Ek M, Hesla J, Cain JM, Figge DC, Greer BE. Glassy cell carcinoma of the 
cervix redefined. Obstet Gynecol 1988;71:837-841. 
17. McKelvey JL, Goodlin RR. Adenoma malignum of the cervix: a cancer of deceptively 
innocent histological pattern. Cancer 1963;16: 549-557. 
18. Musa AG, Hughes RR, Coleman SA. Adenoid cystic carcinoma of the cervix: a report of 17 
cases. Gynecol Oncol 1985;22:167-173. 
19. Brainard JA, Hart WR. Adenoid basal epithelioma of the uterine cervix. Am J Surg Pathol 
1998;22:965-972. 
20. Kaminski PF, Maier RC. Clear cell adenocarcinoma of the cervix unrelated to 
diethylstilbestrol exposure. Obstet Gynecol 1983;62: 720-727. 
21. Reich O, Tamussino K, Lauhousen M, Pickel H, Haas J, Winter R. Clear cell carcinoma of 
the uterine cervix: pathology and prognosis in surgically treated stage IB-IIB disease in 
women not exposed to in utero diethylstilbestrol. Gynecol Oncol 2000;76:331-335. 
22. Chang T-C, Lai C-H, Tseng C-J, Hsueh S, Huang K-G, Chou H-H. Prognostic factors in 
surgically treated small cell cervical carcinoma followed by adjuvant chemotherapy. Cancer 
1998;83:712-718. 
 [58] 
 
23. Rotmensch J, Rosenshein NB, Woodruff JD. Cervical sarcoma: a review. Obstet Gynecol 
Surv 1983;38:456-460. 
24. Daya DA, Scully RE. Sarcoma botryoides of the uterine cervix in young women: a 
clinicopathological study of 13 cases. Gynecol Oncol 1988;29:290-304. 
25. Sharma NK, Sorosky JI, Bender D, Fletcher MS, Sood AK. Malignant mixed müllerian tumor 
(MMMT) of the cervix. Gynecol Oncol 2005;97:442-445. 
26. Komaki R, Cox JD, Hansen RM, Gunn WG, Greenberg M. Malignant lymphoma of the 
uterine cervix. Cancer 1984;54: 1699-1704. 
27. Mordel N, Mor-Yosef S, Ben-Baruch N, Anteby SO. Malignant melanoma of the uterine 
cervix: case report and review of the literature. Gynecol Oncol 1989;32:375-380. 
28.  Santosa JT, Kucora PR, Ray J. Primary malignant melanoma of the uterine cervix: two case 
reports and a century's review. Obstet Gynecol Surv 1990;45:733-744. 
29. Lai C-H, Huang K-G, Hong J-H, Lee C-L, Chou H-H, Chang T-C, et al. Randomized trial of 
surgical staging (extraperitoneal or laparoscopic) versus clinical staging in locally advanced 
cervical cancer. Gynecol Oncol 2003;89:160-167. 
30. Dargent D, Martin X, Mathevet P. Laparoscopic assessment of sentinel lymph nodes in early 
cervical cancer. Gynecol Oncol 2000;79:411-415. 
31. Van Dam PA, Hauspy J, van der Hayden T, Sonnemans H, Spaepen A, Eggenstein G, et al. 
Intraoperative sentinel node identification with Technitium-99m-labelled nanocolloid in 
patients with cancer of the uterine cervix: a feasibility study. Int J Gynecol Cancer 
2003;13:182-186. 
32. Burghardt E, Girardi F. Local spread of cervical cancer. In: Burghardt E, ed. Surgical 
gynecologic oncology. New York: Thieme, 1993:203-212. 
33. Sutton GP, Bundy BN, Delgado G, Sevin BU, Creasman WT, Major FJ, et al. Ovarian 
metastases in stage IB carcinoma of the cervix: a Gynecologic Oncology Group study. Am J 
Obstet Gynecol 1992;166:50-53. 
 [59] 
 
34. Bisseling KC, Bekkers RL, Rome RM, Quinn MA. Treatment of microinvasive 
adenocarcinoma of the uterine cervix: a retrospective study and review of the literature. 
Gynecol Oncol 2007; 107:424. 
35. Selman TJ, Luesley DM, Murphy DJ, Mann CH. Is radical hysterectomy for early stage 
cervical cancer an outdated operation? BJOG 2005; 112:363. 
36. Kolstad P. Follow-up study of 232 patients with stage Ia1 and 411 patients with stage Ia2 
squamous cell carcinoma of the cervix (microinvasive carcinoma). Gynecol Oncol 1989; 
33:265. 
37. Wright JD, Nathavithrana Ret al. Fertility-conserving surgery for young women with stage 
IA1 cervical cancer: safety and access. Obstet Gynecol 2010; 115:585. 
38. Smith JR, Boyle DC, Corless DJ, et al. Abdominal radical trachelectomy: a new surgical 
technique for the conservative management of cervical carcinoma. Br J Obstet Gynaecol 
1997; 104:1196. 
39. Piver M, Rutledge F, Smith J. Five classes of extended hysterectomy for women with cervical 
cancer. Obstet Gynecol 1974;44:265-272. 
40. Wertheim E. The extended abdominal operation for carcinoma uteri (based on 500 operative 
cases Am J Obstet 1912;66:169-174. 
41. Meigs J. Carcinoma of the cervix: the Wertheim operation. Surg Gynecol Obstet 
1944;78:195-199. 
42. Querleu D, Morrow CP. Classification of radical hysterectomy. Lancet Oncol 2008;9:297-
303. 
43. Landoni F, Maneo A, Cormio G, et al. Class II versus class III radical hysterectomy in stage 
IB-IIA cervical cancer: a prospective randomized study. Gynecol Oncol 2001; 80:3. 
44. Frumovitz M, Ramirez PT. Total laparoscopic radical hysterectomy: surgical technique and 
instrumentation. Gynecol Oncol 2007; 104:13. 
45. Chen Y, Xu H, Li Y, et al. The outcome of laparoscopic radical hysterectomy and 
lymphadenectomy for cervical cancer: a prospective analysis of 295 patients. Ann Surg Oncol 
2008; 15:2847. 
 [60] 
 
46. Nezhat FR, Datta MS, Liu C, et al. Robotic radical hysterectomy versus total laparoscopic 
radical hysterectomy with pelvic lymphadenectomy for treatment of early cervical cancer. 
JSLS 2008; 12:227. 
47. Fanning J, Fenton B, Purohit M. Robotic radical hysterectomy. Am J Obstet Gynecol 2008; 
198:649]. 
48. Wright JD, Grigsby PW, Rader JS, et al. Effect of a T0 radical hysterectomy specimen on 
survival for early stage cervical cancer. Gynecol Oncol 2007; 107:280. 
49. Gold MA, Tian C, Whitney CW, et al. Surgical versus radiographic determination of para-
aortic lymph node metastases before chemoradiation for locally advanced cervical carcinoma: 
a Gynecologic Oncology Group Study. Cancer 2008; 112:1954. 
50. Peters WA 3rd, Liu PY, Barrett RJ 2nd, et al. Concurrent chemotherapy and pelvic radiation 
therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery 
in high-risk early-stage cancer of the cervix. J Clin Oncol 2000; 18:1606. 
51.  Green J, Kirwan J, Tierney J, et al. Concomitant chemotherapy and radiation therapy for 
cancer of the uterine cervix. Cochrane Database Syst Rev 2005; :CD002225. 
52.  Inoue T, Morita K. The prognostic significance of number of positive nodes in cervical 
carcinoma stages IB, IIA, and IIB. Cancer 1990; 65:1923. 
53.  Tanaka Y, Sawada S, Murata T. Relationship between lymph node metastases and prognosis 
in patients irradiated postoperatively for carcinoma of the uterine cervix. Acta Radiol Oncol 
1984; 23:455. 
54. Metcalf KS, Johnson N, Calvert S, Peel KR. Site specific lymph node metastasis in carcinoma 
of the cervix: Is there a sentinel node? Int J Gynecol Cancer 2000; 10:411. 
55. Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration (CCCMAC). Reducing 
uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient 
data meta-analysis. Cochrane Database Syst Rev 2010;:CD008285. 
56. Delgado G, Bundy B, Zaino R, et al. Prospective surgical-pathological study of disease-free 
interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic 
Oncology Group study. Gynecol Oncol 1990; 38:352. 
 [61] 
 
57. 32 Van de Putte G, Lie AK, Vach W, et al. Risk grouping in stage IB squamous cell cervical 
carcinoma. Gynecol Oncol 2005; 99:106. 
58. 33 Grigsby PW. Primary radiotherapy for stage IB or IIA cervical cancer. J Natl Cancer Inst 
Monogr 1996; :61. 
59. Sedlis A, Bundy BN, Rotman MZ, et al. A randomized trial of pelvic radiation therapy versus 
no further therapy in selected patients with stage IB carcinoma of the cervix after radical 
hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study. Gynecol 
Oncol 1999; 73:177. 
60. Rotman M, Sedlis A, Piedmonte MR, et al. A phase III randomized trial of postoperative 
pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a 
gynecologic oncology group study. Int J Radiat Oncol Biol Phys 2006; 65:169. 
61. Landoni F, Maneo A, Colombo A, et al. Randomised study of radical surgery versus 
radiotherapy for stage Ib-IIa cervical cancer. Lancet 1997; 350:535. 
62. Bansal N, Herzog TJ, Shaw RE, et al. Primary therapy for early-stage cervical cancer: radical 
hysterectomy vs radiation. Am J Obstet Gynecol 2009; 201:485. 
63. Monk BJ, Tewari K, Burger RA, et al. A comparison of intracavitary versus interstitial 
irradiation in the treatment of cervical cancer. Gynecol Oncol 1997; 67:241. 
64. Patel FD, Sharma SC, Negi PS, et al. Low dose rate vs. high dose rate brachytherapy in the 
treatment of carcinoma of the uterine cervix: a clinical trial. Int J Radiat Oncol Biol Phys 
1994; 28:335. 
65. Hareyama M, Sakata K, Oouchi A, et al. High-dose-rate versus low-dose-rate intracavitary 
therapy for carcinoma of the uterine cervix: a randomized trial. Cancer 2002; 94:117. 
66. Lertsanguansinchai P, Lertbutsayanukul C, Shotelersuk K, et al. Phase III randomized trial 
comparing LDR and HDR brachytherapy in treatment of cervical carcinoma. Int J Radiat 
Oncol Biol Phys 2004; 59:1424. 
67. Keys HM, Bundy BN, Stehman FB, et al. Radiation therapy with and without extrafascial 
hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic 
Oncology Group. Gynecol Oncol 2003; 89:343. 
 [62] 
 
68. Vistad I, Fosså SD, Dahl AA. A critical review of patient-rated quality of life studies of long-
term survivors of cervical cancer. Gynecol Oncol 2006; 102:563. 
69. Frumovitz M, Sun CC, Schover LR, et al. Quality of life and sexual functioning in cervical 
cancer survivors. J Clin Oncol 2005; 23:7428. 
70. Tanaka Y, Sawada S, Murata T. Relationship between lymph node metastases and prognosis 
in patients irradiated postoperatively for carcinoma of the uterine cervix. Acta Radiol Oncol 
1984; 23:455. 
71. Marchiolé P, Buénerd A, Benchaib M, et al. Clinical significance of lympho vascular space 
involvement and lymph node micrometastases in early-stage cervical cancer: a retrospective 
case-control surgico-pathological study. Gynecol Oncol 2005; 97:727. 
72. Silva LB, Silva-Filho AL, Traiman P, et al. Sentinel node detection in cervical cancer with 
(99m)Tc-phytate. Gynecol Oncol 2005; 97:588. 
73. Lentz SE, Muderspach LI, Felix JC, et al. Identification of micrometastases in histologically 
negative lymph nodes of early-stage cervical cancer patients. Obstet Gynecol 2004; 103:1204. 
74. Juretzka MM, Jensen KC, Longacre TA, et al. Detection of pelvic lymph node 
micrometastasis in stage IA2-IB2 cervical cancer by immunohistochemical analysis. Gynecol 
Oncol 2004; 93:107. 
